{"groups":[{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab","id":"FG000","title":"Experimental Arm for Chemo Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Standard Chemotherapy for 4 to 6 cycles, followed by Observation","id":"FG001","title":"Control Arm for Chemo Cohort: Chemotherapy, Then Observation"},{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab","id":"FG002","title":"Experimental Arm for IO Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Ipilimumab every 6 weeks and Nivolumab every 2 or 3 weeks for up to 2 years.","id":"FG003","title":"Control Arm for IO Cohort: Ipilimumab and Nivolumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"6"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"87"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"13"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Not Treated"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"Patient moved to off label supply of durvalumab following declaration of study closure by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Functional decline due to medical comorbidities"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Required use of prohibited concomitant treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"The patient is not dead."},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}],"type":"Patient continuing with nivolumab treatment beyond declaration of study closure by sponsor"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"17"},{"groupId":"FG003","numSubjects":"23"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"38"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"22"},{"groupId":"FG002","numSubjects":"17"},{"groupId":"FG003","numSubjects":"23"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}